Comparison of generic and lung cancer-specific quality of life instruments for predictive ability of survival in patients with advanced lung cancer

Basit Öğe Kaydı
dc.authoridCelik, Pinar/0000-0003-1015-8189
dc.authoridBaydur, Hakan/0000-0002-4439-3569
dc.authoridErbaycu, Ahmet Emin/0000-0001-6618-6774;
dc.authorwosidCelik, Pinar/AFT-6588-2022
dc.authorwosidBaydur, Hakan/J-8043-2012
dc.authorwosidErbaycu, Ahmet Emin/K-2948-2017
dc.authorwosid, osman/HRD-6024-2023
dc.authorwosid, Osman/AGR-7980-2022
dc.authorwosidEser, Sultan/JXL-7706-2024
dc.contributor.authorEser, Sultan
dc.contributor.authorGoksel, Tuncay
dc.contributor.authorErbaycu, Ahmet Emin
dc.contributor.authorBaydur, Hakan
dc.contributor.authorBasarik, Burcu
dc.contributor.authorYanik, Aysen Oz
dc.contributor.authorGursul, Kader Kiyar
dc.date.accessioned2024-06-12T11:07:54Z
dc.date.available2024-06-12T11:07:54Z
dc.date.issued2016
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackground: Our purpose is to examine the relationship of Health related quality of life measured by EORTC QLQc30, QLQ-LC13; FACT-L, LCSS, Eq5D) with survival in advanced lung cancer patients. A total of 299 Lung Cancer (LC) patients were, included in this national multicenter Project entitled of the LC Quality of Life Project (AKAYAK). Baseline scores were analyzed by using Cox's proportional hazard regression to identify factors that influenced survival. Univariate and multivariate models were run for each of the scales included in the study. Results: Mean and median survival were 12.5 and 8.0 months respectively. Clinical stage (as TNM), comorbidity; symptom scales of fatigue, insomnia, appetit loss and constipation were associated with survival after adjustment for age and sex. Global, physical and role functioning scales of QLQc30; physical and functional scales of LCS and TOI of the FACT-L was also associated with survival. Mobility and Usual activities dimensions of the Eq5D; Physical functioning and the constipation symptom scale of the QLQ-c30; and LCS and TOI scores of the FACT-L remained statistically significant after adjustment. LC13 and LCSS scales were not predictors of survival. Conclusions: HRQOL serves as an additional predictive factor for survival that supplements traditional clinical factors. Besides the strong predictive ability of ECOG on survival, FACT-L and the Eq5D are the most promising HRQOL instruments for this purpose.en_US
dc.identifier.doi10.1186/s40064-016-3492-7
dc.identifier.issn2193-1801
dc.identifier.pmid27818871en_US
dc.identifier.scopus2-s2.0-84991764891en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.urihttps://doi.org/10.1186/s40064-016-3492-7
dc.identifier.urihttps://hdl.handle.net/20.500.14551/22224
dc.identifier.volume5en_US
dc.identifier.wosWOS:000391810900013en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer International Publishing Agen_US
dc.relation.ispartofSpringerplusen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectLung Canceren_US
dc.subjectHRQOLen_US
dc.subjectPrognostic Factorsen_US
dc.subjectSurvivalen_US
dc.subjectCooperative-Oncology-Groupen_US
dc.subjectPrognostic-Factorsen_US
dc.subjectEuropean-Organizationen_US
dc.subjectClinical-Trialsen_US
dc.subjectEortc Qlq-C30en_US
dc.subjectReceiving Chemotherapyen_US
dc.subjectFunctional Assessmenten_US
dc.subjectPerformance Statusen_US
dc.subjectReported Healthen_US
dc.subjectQuestionnaireen_US
dc.titleComparison of generic and lung cancer-specific quality of life instruments for predictive ability of survival in patients with advanced lung canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu